Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

EMEA Recommends Updated Label Warnings for Etoricoxib-Containing Drugs LONDON -- June 27, 2008 -- Finalising a review of the benefits and risks of etoricoxib-containing medicines, the European Medicines Agency (EMEA) has concluded that these medicines can be used to treat rheumatoid arthritis and ankylosing spondylitis, but recommended that their product information should be updated concerning the risk of cardiovascular side effects. In the context of the evaluation of the application for extension of indication, concerns were raised over the cardiovascular safety of etoricoxib-containing medicines when used to treat ankylosing spondylitis at a dose of 90 mg QD. These concerns also extended to the treatment of rheumatoid arthritis, which is used at the same dose. The EMEA's Committee for Medicinal Products for Human Use (CHMP) was asked to look at the benefits and risks of etoricoxib for the long-term treatment of rheumatoid arthritis and ankylosing spondylitis to determine whether the marketing authorisations for these medicines should be maintained, varied, suspended, or withdrawn across the European Union. The review did not concern osteoarthritis and acute gouty arthritis. Following review of all available data, the CHMP concluded that the benefits of etoricoxib-containing medicines outweigh their risks for the treatment of rheumatoid arthritis and ankylosing spondylitis when used at a dose of 90 mg QD, and therefore recommended that the extension of indication to include ankylosing spondylitis be granted, and that the indication in rheumatoid arthritis could be maintained. However, the CHMP recommended updating the existing contraindication in patients with hypertension that is not adequately controlled to state that patients whose blood pressure is persistently above 140/90 mm Hg and has not been adequately controlled should not take the medicine. In addition, the CHMP concluded that warnings should be added to the product information for etoricoxib-containing medicines, stating that high blood pressure should be controlled before treatment is begun and should be monitored for 2 weeks after the start of treatment and regularly thereafter. Physicians should prescribe etoricoxib-containing medicines according to the updated product information. Physicians are advised to monitor closely any signs or symptoms of cardiovascular side effects. SOURCE: European Medicines Agency E-mail this page to a friend or colleague! To print, use this version